PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 112 filers reported holding PHATHOM PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.31 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,407,000 | -38.1% | 1,100,000 | -14.6% | 0.89% | -33.0% |
| Q2 2023 | $18,437,000 | +94.8% | 1,287,500 | -2.9% | 1.32% | +87.8% |
| Q1 2023 | $9,464,071 | -37.5% | 1,325,500 | -1.8% | 0.70% | -45.0% |
| Q4 2022 | $15,147,000 | -17.8% | 1,350,000 | -18.9% | 1.28% | -10.0% |
| Q3 2022 | $18,436,000 | +51.7% | 1,663,943 | +15.6% | 1.42% | +66.1% |
| Q2 2022 | $12,153,000 | +151.5% | 1,440,000 | +305.6% | 0.86% | +231.3% |
| Q1 2022 | $4,833,000 | -15.5% | 355,000 | +22.2% | 0.26% | +23.3% |
| Q4 2021 | $5,717,000 | – | 290,595 | – | 0.21% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 2,484,274 | $27,873,554 | 11.71% |
| Frazier Life Sciences Management, L.P. | 8,407,152 | $94,328,245 | 5.86% |
| Abingworth LLP | 1,435,106 | $16,101,889 | 5.25% |
| Opaleye Management Inc. | 417,500 | $4,684,350 | 1.63% |
| 683 Capital Management, LLC | 1,350,000 | $15,147,000 | 1.28% |
| Newtyn Management, LLC | 484,074 | $5,431,310 | 1.12% |
| Penn Mutual Asset Management | 62,802 | $704,638 | 0.79% |
| StepStone Group LP | 422,085 | $4,735,794 | 0.62% |
| MPM BioImpact LLC | 195,942 | $2,198,469 | 0.57% |
| Avidity Partners Management LP | 1,900,000 | $21,318,000 | 0.46% |